MYC in breast tumor progression

Expert Review of Anticancer Therapy

Volumn 8, Issue 10, 2008, Pages 1689-1698

  Chen, Yinghua ^a   Olopade, Olufunmilayo I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

BRCA1; Breast cancer; Clinical trial; MYC; Targeted therapy; Transcription regulation; Tumor progression

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 5126; BRCA1 PROTEIN; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; MESSENGER RNA; MYC PROTEIN; NEUROGENIC DIFFERENTIATION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANGIOGENESIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE REGULATION; CELL GROWTH; CELL TRANSFORMATION; CLINICAL TRIAL; DOWNSTREAM PROCESSING; DRUG EFFICACY; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENES, BRCA1; GENES, MYC; HUMANS; TRANSCRIPTION, GENETIC;

EID: 55249122940     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.10.1689     Document Type: Review

References (108)

1. Vennstrom B, Sheiness D, Zabielski J, Bishop JM. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol. 42(3), 773-779 (1982).
2. Escot C, Theillet C, Lidereau R et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl Acad. Sci. USA 83(13), 4834-4838 (1986).
3. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6(8), 635-645 (2005).
4. Pelengaris S, Khan M. The many faces of c-MYC. Arch. Biochem. Biophys. 416(2), 129-136 (2003).
5. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 22(56), 9007-9021 (2003).
6. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2(10), 764-776 (2002).
7. Altschul SF, Madden TL, Schaffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17), 3389-3402 (1997).
8. Ledent V, Paquet O, Vervoort M. Phylogenetic analysis of the human basic helix-loop-helix proteins. Genome Biol. 3(6), research0030.1-research0030.18 (2002).
9. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2), 193-205 (2003).
10. Solomon DL, Amati B, Land H. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res. 21(23), 5372-5376 (1993).
11. Grandori C, Mac J, Siebelt F, Ayer DE, Eisenman RN. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J. 15(16), 4344-4357 (1996).
12. O'Hagan RC, Schreiber-Agus; N, Chen K et al. Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat. Genet. 24(2), 113-119 (2000).
13. Winston RL, Gottesfeld JM. Rapid identification of key amino-acid-DNA contacts through combinatorial peptide synthesis. Chem. Biol. 7(4), 245-251 (2000).
14. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 251(4990), 186-189 (1991).
15. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16, 653-699 (2000).
16. Boyd KE, Farnham PJ. Identification of target genes of oncogenic transcription factors. Proc. Soc. Exp. Biol. Med. 222(1), 9-28 (1999).
17. Corzo C, Corominas JM, Tusquets I et al. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet. Cytogenet. 165(2), 151-156 (2006).
18. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP. c-myc amplifications in primary breast carcinomas and their local recurrences. J. Clin. Pathol. 59(4), 424-428 (2006).
19. Bieche I, Laurendeau I, Tozlu S et al. Quantitation of MYC gene expression in sporadic breast rumors with a real-time reverse transcription-PCR assay. Cancer Res. 59(12), 2759-2765 (1999).
20. Le MG, Mathieu MC, Douc-Rasy S et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int. J. Cancer 84(6), 562-567 (1999).
21. Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br. J. Cancer 81(8), 1385-1391 (1999).
22. Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T. Amplification of c-myc gene and overexpression. of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin. Biochem. 34(7), 557-562 (2001).
23. Naidu R, Wahab NA, Yadav M, Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochernistry and differential polymerase chain reaction. Int. J. Mol. Med. 9(2), 189-196 (2002).
24. Robanus-Maandag EC, Bosch CA, Kristel PM et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J. Pathol. 201(1), 75-82 (2003).
25. Shimada M, Imura J, Kozaki T et al. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Oncol. Rep. 13(4), 633-641 (2005).
26. Park K, Kwak Y, Kim J, Lim S, Han S. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected. breast cancers. Hum. Pathol. 36(6), 634-639 (2005).
27. Rodriguez-Pinilla SM, Jones RL, Lambros MB et al. MYC amplificadon in breast cancer: a chromogenic in situ hybridisation study. J. Clin. Pathol. 60(9), 1017-1023 (2007).
28. Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod. Pathol. 14(10), 1030-1035 (2001).
29. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J, Pavelic K. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp. Mol. Pathol. 79(1), 42-50 (2005).
30. Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp. Mol. Pathol. 82(1), 85-90 (2007).
31. Al-Kuraya K, Schraml P, Sheikh S et al. Predominance of high-grade pathway in breast cancer development of Middle East women. Mod. Pathol. 18(7), 891-897 (2005).
32. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br. J. Cancer 90 (8), 1612-1619 (2004).
33. Aulmann S, Bentz M, Sinn HP. C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 74(1), 25-31 (2002).
34. Janocko LE, Brown KA, Smith CA et al. Distinctive patterns of Her-2/nea, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 46(3), 136-149 (2001).
35. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER-2/ neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 5(2), R30-R36 (2003).
36. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast lumours. Nature 406(6797), 747-752 (2000).
37. Sorlie T, Peron CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98(19), 10869-10874 (2001).
38. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
39. Charafe-Jauffret E, Ginestier C, Monville F et al. How to best classify breast cancer: conventional and novel classifications (review). Int. J. Oncol. 27(5), 1307- 1313 (2005).
40. Bertucci F, Finetti P, Cervera N et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 66(9), 4636-4644 (2006).
41. Al-Kuraya K, Schraml P, Torhorst J et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64(23), 8534-8540 (2004).
42. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100(18), 10393-10398 (2003).
43. Grushko TA, Dignam JJ, Das S et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 10(2), 499-507 (2004).
44. Wei M, Grushko TA, Dignam J et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 65 (23), 10692-10699 (2005).
45. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J. Biol. Chem. 281(46), 34725-34729 (2006).
46. He TC, Sparks AB, Rage, C et al Identification of c-MYC as a target of the APC pathway. Science 28 1(5382), 1509-1512 (1998).
47. Ozaki S, Ikeda S, Ishizaki Y et al. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol. Rep. 14(6), 1437-1443 (2005).
48. Cowling VH, D'Cruz CM, Chodosh LA, Cole MD. c-Myc transforms human mammary epithelial cells through repression of the Writ inhibitors DKK1 and SFRP1. Mol. Cell Biol. 27(14), 5135-5146 (2007).
49. Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notchi transcriptional target and a requisite for Notchi-induced mammary tumorigenesis in mice. Proc. Natl Acad. Sci. USA 103(24), 9262-9267 (2006).
50. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 66 (3), 1517-1525 (2006).
51. Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor β growth arrest program. Proc. Natl Acad. Sci. USA 98 (3), 992-999 (2001).
52. Yagi K, Furuhashi M, Aoki H et al. c-myc is a downstream target of the Smad pathway. J. Biol. Chem. 277(1), 854-861 (2002).
53. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 63 (13), 3783-3790 (2003).
54. Lutterbach B, Hann SR. Overexpression of c-Myc and cell immortalization alters c-Myc phosphorylation. Oncogene 14(8), 967-975 (1997).
55. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278(51), 51606-51612 (2003).
56. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett. 580(24), 5647-5652 (2006).
57. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin. Cancer Biol. 16(4), 253-264 (2006).
58. Zhang XY, DeSalle LM, Patel JH et al. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc. Natl Acad. Sci. USA 102(39), 13968-13973 (2005).
59. Gururaj AE, Singh RR, Rayala SK et al. MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc. Natl Acad. Sci. USA 103(17), 6670-6675 (2006).
60. Li CM, Margolin AA, Salas M et al. PEG10 is a c-MYC target gene in cancer cells. Cancer Res. 66(2), 665-672 (2006).
61. Ono R, Kobayashi S, Wagatsuma H et al. A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 73 (2), 232-237 (2001).
62. Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK. Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues. Mol. Cancer Res. 3 (9), 503-509 (2005).
63. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23(9), 1949-1956 (2004).
64. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19(4), 1207-1225 (2001).
65. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl Cancer Inst. 89(2), 139-147 (1997).
66. Mizukami Y, Fujiki K, Duerr EM et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J. Biol. Chem. 281(20), 13957-13963 (2006).
67. Wu Y, Hooper AT, Zhong Z et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 119(7), 1519-1529 (2006).
68. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66-71 (1994).
69. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet. Epidemiol. 18(2), 173-190 (2000).
70. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343(8899), 692-695 (1994).
71. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
72. Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev. 10 (5), 467-473 (2001).
73. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20), 1401-1408 (1997).
74. Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. J. Cell Physiol. 196(1), 19-41 (2003).
75. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4(9), 665-676 (2004).
76. Yang Q, Sakurai T, Mori I et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 92(1), 54-60 (2001).
77. Taylor J, Lymboura M, Pace PE et al. An important role for BRC41 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int. J. Cancer 79(4), 334-342 (1998).
78. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int. J. Cancer 80(6), 823-826 (1999).
79. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl Cancer Inst. 94(18), 1396-1406 (2002).
80. Couch FJ, DeShano ML, Blackwood MA et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336(20), 1409-1415 (1997).
81. Wang C, Horiuchi A, Imai T et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J. Pathol. 202(2), 215-223 (2004).
82. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43), 5864-5874 (2006).
83. Kentsis A, Gordon RE, Borden KL. Control of biochemical reactions through supramolecular RING domain self-assembly. Proc. Natl Acad. Sci. USA 99(24), 15404-15409 (2002).
84. Kentsis A, Gordon RE, Borden KL. Self-assembly properties of a model RING domain. Proc. Natl Acad. Sci. USA 99(2), 667-672 (2002).
85. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J. 20(16), 4547-4559 (2001).
86. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11(1), 68-76 (1997).
87. Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett. 400(1), 25-30 (1997).
88. Marquis ST, Rajan JV, Wynshaw-Boris A et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet. 11(1), 17-26 (1995).
89. Ruffner H, Verma IM. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc. Natl. Acad. Sci. USA 94(14), 7138-7143 (1997).
90. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408(6811), 429-432 (2000).
91. Fan S, Wang J, Yuan R et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284(5418), 1354-1356 (1999).
92. Zhang HT, Zhang X, Zhao HZ et al. Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene 14(24), 2863-2869 (1997).
93. Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem. 273(39), 25388-25392 (1998).
94. Yu X, Baer R. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J. Biol. Chem. 275(24), 18541-18549 (2000).
95. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. USA 96(9), 4983-4988 (1999).
96. Wang Q, Zhang H, Kajino K, Greene MI. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17(15), 1939-1948 (1998).
97. Schlegel BP, Green VJ, Ladias JA, Parvin JD. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10α in activated transcription. Proc. Natl Acad. Sci. USA 97(7), 3148-3153 (2000).
98. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa. H. BRCA1 regulates p53-dependent gene expression. Proc. Natl Acad. Sci. USA 95(5), 2302-2306 (1998).
99. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19(3), 254-256 (1998).
100. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277(23), 20965-20973 (2002).
101. Kennedy RD, Gorski JJ, Quinn JE et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res. 65(22), 10265-10272 (2005).
102. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 16(4), 318-330 (2006).
103. Carbone GM, McGuffie E, Napoli S et al. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming ofigonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res. 32(8), 2396-2410 (2004).
104. Christensen LA, Finch RA, Booker AJ, Vasquez KM. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res. 66(8), 4089-4094 (2006).
105. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res. 62(11), 3126-3131 (2002).
106. Wang YH, Liu S, Zhang G et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 7(2), R220-R228 (2005).
107. El-Andaloussi S, Johansson H, Magnusdottir A, Jarver P, Lundberg P, Langel U. TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J. Control. Release 110(1), 189-201 (2005).
108. Reinholz MM, Dueck AC, Lingle WL et al. The concordance between NCCTG's and NSABP's C-myc FISH assays. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 22110).